½ÃÀ庸°í¼­
»óǰÄÚµå
1519777

Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çü, ½ÃÇè À¯Çü, °Ë»ç À¯Çü, ¿ëµµ, Áö¿ªº°(2024-2032³â)

Histology and Cytology Market Report by Product, Type of Examination, Test Type, Application, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 148 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 165¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 394¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 9.92%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

Á¶Á÷ ¹× ¼¼Æ÷ÇÐÀº µ¿¹°°ú ½Ä¹°ÀÇ Á¶Á÷°ú ¼¼Æ÷ÀÇ È­ÇÐ, ±¸Á¶, ±â´ÉÀ» Çö¹Ì°æ ¼öÁØ¿¡¼­ ´Ù·ç´Â »ý¹°ÇÐÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. ¾Ï, ÀڱðæºÎÁúȯ, °áÇÙ, Àΰ£À¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °¨¿°, ÀÌ»ó Áõ½Ä, ¿°Áõ¼º Áúȯ, ¹éÇ÷º´, õ¿¬µÎ, ±¤°ßº´ µîÀÇ Áúº´À» Áø´ÜÇÏ´Â µ¥ ÀÇ·áÁøÀ» µ½½À´Ï´Ù. ¶ÇÇÑ Áø´Ü¹ýÀÇ ¹Î°¨µµ, ƯÀ̵µ, Á¤È®µµ¸¦ Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ±× °á°ú, Àü ¼¼°è º´¿ø, Áø·á¼Ò, ¿¬±¸°³¹ß(R&D) ±â°ü¿¡¼­ Æø³Ð°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀå µ¿Çâ :

ÇöÀç Àü ¼¼°è¿¡¼­ ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÓ»ó °Ë»ç¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ÇÔ²² ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ¼¼Æ÷ Áø´Ü¿¡¼­ µðÁöÅÐ ¼Ö·ç¼ÇÀÇ ÅëÇÕÀÌ ÁøÇàµÇ¾î 1Â÷ Áø´Ü µ¥ÀÌÅ͸¦ ½Å¼ÓÇÏ°Ô ÇØ¼®ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â °Íµµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä Á¦Á¶¾÷üµéÀº ¼¼Æ÷ Áø´Ü »ùÇÃÀÇ ½Å¼ÓÇÑ ÇöÀå Æò°¡¸¦ Áö¿øÇϱâ À§ÇØ »õ·Î¿î ÷´Ü ¼¼Æ÷ Áø´Ü ½Ã½ºÅÛÀ» Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¼¼Æ÷ ¼ººÐÀ» ½Ã°¢È­ÇÏ´Â ¸é¿ªÁ¶Á÷È­ÇÐ(IHC)ÀÇ Àαâ Áõ°¡¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Àü ¼¼°è¿¡¼­ º´¸® ½ÇÇè½ÇÀÇ Ç¥ÁØÈ­°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â Áø´Ü ±â¼ú ¹× ºÐÀÚ ±â¼úÀÇ ±â¼úÀû Áøº¸¿Í ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã·´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¼¼°è ÇコÄɾî ÀÎÇÁ¶ó°¡ °³¼±µÇ¸é¼­ ¾÷°è ÅõÀÚÀڵ鿡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå ±â¾÷Àº °í°´ ±â¹ÝÀ» È®´ëÇϱâ À§ÇØ Àμö, ÇÕº´, Á¦ÈÞ ¹× Çù·Â¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÁ¦Ç°À» Ãâ½ÃÇÏ°í ±ÔÁ¦ ´ç±¹ÀÇ Á¦Ç° ½ÂÀÎÀ» ȹµæÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡? COVID-19°¡ ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀåÀÇ Á¦Ç° À¯Çüº° ºÐ·ù´Â?
  • ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀåÀÇ °Ë»ç À¯Çüº° ºÐ¼®Àº?
  • ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀåÀÇ °Ë»ç À¯Çüº° ºÐ¼®Àº?
  • ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ ¾îÇÁ·ÎÄ¡
    • Åé´Ù¿î ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Á¶Á÷ ¹× ¼¼Æ÷ÇÐ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ±â±â ¹× ºÐ¼® ¼ÒÇÁÆ®¿þ¾î ½Ã½ºÅÛ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼Ò¸ðǰ°ú ½Ã¾à
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ½ÃÇè À¯Çüº°

  • Á¶Á÷
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼¼Æ÷
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : °Ë»ç À¯Çüº°

  • Çö¹Ì°æ°Ë»ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ºÐÀÚÀ¯ÀüÇÐ °Ë»ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • À¯¼¼Æ÷ºÐ¼®
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ÀǾàǰ ¹ß°ß°ú ¼³°è
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÀÓ»ó Áø´Ü
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • POC(Point of Care)
      • ºñPOC(Point of Care)
    • ½ÃÀå ¿¹Ãø
  • ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀïÀÇ Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Carl Zeiss AG
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • Hologic Inc.
    • Koninklijke Philips N.V.
    • Merck KGaA
    • Olympus Corporation
    • PerkinElmer Inc.
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
    • Trivitron Healthcare
KSA 24.08.16

The global histology and cytology market size reached US$ 16.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.92% during 2024-2032.

Histology and cytology are branches of biology dealing with chemistry, structure and function of tissues and cells of animals and plants at a microscopic level. They assist medical staff in diagnosing diseases, such as cancer, cervical disease, tuberculosis, human papilloma virus (HPV) infection, abnormal growth, inflammatory diseases, leukemia, smallpox, and rabies. They also help enhance the sensitivity, specificity and accuracy of diagnostic methods. As a result, they find extensive applications in hospitals, clinics, and research and development (R&D) institutes across the globe.

Histology and Cytology Market Trends:

At present, there is a rise in the number of cancer patients across the globe. This, along with the favorable reimbursement policies for laboratory tests, represents one of the key factors driving the market. Moreover, the growing integration of digital solutions in cytological diagnosis aids in rapidly interpreting primary diagnostic data, which is positively influencing the market. In addition, major manufacturers are launching new and advanced cytology systems for helping in the rapid on-site evaluation of cytology samples. This, coupled with the rising traction of immunohistochemistry (IHC) for visualizing cellular components, is propelling the growth of the market. Besides this, there is an increase in the standardization of pathological laboratories around the world. This, along with technological advancements in diagnostic and molecular techniques, is contributing to the growth of the market. Additionally, increasing awareness about the advanced therapeutics and enhanced healthcare infrastructure worldwide is offering lucrative growth opportunities to industry investors. Furthermore, key market players are focusing on acquisitions, mergers, partnerships, and collaborations to expand their customer base. They are also launching new products and receiving product approvals from regulatory authorities, which is projected to bolster the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global histology and cytology market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, type of examination, test type and application.

Breakup by Product:

Instruments and Analysis Software System

Consumable and Reagents

Breakup by Type of Examination:

Histology

Cytology

Breakup by Test Type:

Microscopy Tests

Molecular Genetics Tests

Flow Cytometry

Breakup by Application:

Drug Discovery and Designing

Clinical Diagnostics

Point-of-Care (PoC)

Non-Point-of-Care

Research

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Carl Zeiss AG, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Koninklijke Philips N.V., Merck KGaA, Olympus Corporation, PerkinElmer Inc., Sysmex Corporation, Thermo Fisher Scientific Inc. and Trivitron Healthcare.

Key Questions Answered in This Report

  • 1. What was the size of the global histology and cytology market in 2023?
  • 2. What is the expected growth rate of the global histology and cytology market during 2024-2032?
  • 3. What are the key factors driving the global histology and cytology market?4. What has been the impact of COVID-19 on the global histology and cytology market?
  • 5. What is the breakup of the global histology and cytology market based on the product?
  • 6. What is the breakup of the global histology and cytology market based on the type of examination?
  • 7. What is the breakup of the global histology and cytology market based on test type?
  • 8. What is the breakup of the global histology and cytology market based on the application?
  • 9. What are the key regions in the global histology and cytology market?
  • 10. Who are the key players/companies in the global histology and cytology market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Histology and Cytology Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Instruments and Analysis Software System
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Consumable and Reagents
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Type of Examination

  • 7.1 Histology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cytology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Test Type

  • 8.1 Microscopy Tests
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Molecular Genetics Tests
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Flow Cytometry
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Drug Discovery and Designing
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinical Diagnostics
    • 9.2.1 Market Trends
    • 9.2.2 Key Segments
      • 9.2.2.1 Point-of-Care (PoC)
      • 9.2.2.2 Non-Point-of-Care
    • 9.2.3 Market Forecast
  • 9.3 Research
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Carl Zeiss AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Hologic Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Koninklijke Philips N.V.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck KGaA
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Olympus Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 PerkinElmer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sysmex Corporation
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Trivitron Healthcare
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦